Enveric Biosciences, Inc. (ENVB) — SEC Filings
Enveric Biosciences, Inc. (ENVB) — 50 SEC filings. Latest: EFFECT (Apr 30, 2026). Includes 29 8-K, 5 10-Q, 4 DEF 14A.
View Enveric Biosciences, Inc. on SEC EDGAR
Overview
Enveric Biosciences, Inc. (ENVB) is a publicly traded company tracked on ReadTheFiling. The most recent enriched filing is a 8-K filed on Dec 11, 2025: Enveric Biosciences, Inc. filed an 8-K on December 11, 2025, reporting on matters submitted to a vote of security holders and financial statements/exhibits. The company, incorporated in Delaware, is located at 245 First Street, Riverview II, 18th Floor, Cambridge, MA 02142.
Sentiment Summary
Across 50 filings, the sentiment breakdown is: 8 bearish, 42 neutral. The dominant filing sentiment for Enveric Biosciences, Inc. is neutral.
Filing Type Overview
Enveric Biosciences, Inc. (ENVB) has filed 1 EFFECT, 29 8-K, 5 10-Q, 4 DEF 14A, 2 10-K, 1 S-1/A, 1 8-K/A, 2 S-1, 4 SC 13G/A, 1 SC 13G with the SEC between Feb 2024 to Apr 2026.
Filings by Year
Recent SEC Filings (50)
Risk Profile
Risk Assessment: Of ENVB's 42 recent filings, 8 were flagged as high-risk, 18 as medium-risk, and 16 as low-risk. The overall risk profile suggests moderate risk with a balanced mix of positive and cautionary disclosures.
Financial Highlights
| Metric | Value |
|---|---|
| Revenue | $0 |
| Net Income | -$6,577,816 |
| EPS | N/A |
| Debt-to-Equity | 0.26 |
| Cash Position | $3,757,594 |
| Operating Margin | N/A |
| Total Assets | $4,362,061 |
| Total Debt | $1,132,061 |
Key Executives
- Joseph Tucker
- Kevin Coveney
- Joseph Tu
Industry Context
Enveric Biosciences operates in the highly competitive biotechnology sector, focusing on developing novel therapeutics for psychiatric and neurological disorders. This field is characterized by long development cycles, significant R&D investment, and high failure rates. The industry is driven by scientific innovation, regulatory approvals, and the ability to secure substantial funding to advance drug candidates through clinical trials.
Top Tags
financial-reporting (7) · delisting (6) · material-agreement (5) · filing (5) · disclosure (5) · corporate-governance (5) · pharmaceuticals (5) · sec-filing (5) · financials (5) · 8-K (4)
Key Numbers
| Metric | Value | Context |
|---|---|---|
| Accumulated Deficit | $112,652,321 | as of September 30, 2025, indicating significant historical losses |
| Net Loss | $6,577,816 | for the nine months ended September 30, 2025, an increase from $6,420,341 in 2024 |
| Cash | $3,757,594 | as of September 30, 2025, up from $2,241,026 at December 31, 2024 |
| Net Cash Used in Operating Activities | $6,356,680 | for the nine months ended September 30, 2025 |
| Net Cash Provided by Financing Activities | $7,890,361 | for the nine months ended September 30, 2025, primarily from equity sales and warrant exercises |
| Reverse Stock Split Ratio | 1-for-15 | effected on January 27, 2025 |
| Research and Development Expenses | $2,408,839 | for the nine months ended September 30, 2025, an increase from $1,873,873 in 2024 |
| Gross cash proceeds | $2.2M | From warrant inducement transaction, contingent on stockholder approval |
| Common Stock closing price | $0.62 | As of October 22, 2025, driving reverse stock split proposal |
| Reverse stock split ratio range | 1-for-5 to 1-for-15 | Proposed to increase per-share price |
| Authorized Common Stock increase | 100M to 5B | Proposed to provide flexibility for future financing |
| Nasdaq Listing Rule threshold | 20% | Issuance of shares exceeding this requires stockholder approval |
| Shares of Common Stock outstanding | 6,219,568 | As of the Record Date, October 13, 2025 |
| Frequency of required meetings | 90 days | If Issuance Proposal is not approved |
| Proxy solicitor fee | $12,500 | Paid to Kingsdale Advisors |
Forward-Looking Statements
- {"claim":"Enveric Biosciences' stock price will experience significant downward pressure.","entity":"ENVB","targetDate":"Q1 2024","confidence":"high"}
- {"claim":"Trading volume and liquidity for ENVB shares will decrease substantially.","entity":"ENVB","targetDate":"Q1 2024","confidence":"high"}
Frequently Asked Questions
What are the latest SEC filings for Enveric Biosciences, Inc. (ENVB)?
Enveric Biosciences, Inc. has 50 recent SEC filings from Feb 2024 to Apr 2026, including 29 8-K, 5 10-Q, 4 DEF 14A. Each filing includes an AI-generated plain-English summary.
What is the overall sentiment of ENVB filings?
Across 50 filings, the sentiment breakdown is: 8 bearish, 42 neutral. The dominant sentiment is neutral.
Where can I find Enveric Biosciences, Inc. SEC filings explained simply?
ReadTheFiling provides AI-powered plain-English summaries of all Enveric Biosciences, Inc. (ENVB) SEC filings, including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, and insider trades.
What are the key financial highlights for Enveric Biosciences, Inc.?
Key financial highlights from Enveric Biosciences, Inc.'s most recent 10-Q include metrics such as revenue, net income, EPS, and debt ratios. Visit the filing detail page for the full breakdown.
What is the investment thesis for ENVB?
The investment thesis for ENVB includes bull, base, and bear case scenarios derived from AI analysis of recent SEC filings.
Who are the key executives at Enveric Biosciences, Inc.?
Key executives identified across Enveric Biosciences, Inc.'s filings include Joseph Tucker, Kevin Coveney, Joseph Tu.
What are the main risk factors for Enveric Biosciences, Inc. stock?
Of ENVB's 42 assessed filings, 8 were flagged high-risk, 18 medium-risk, and 16 low-risk.
What are recent predictions and forward guidance from Enveric Biosciences, Inc.?
Recent forward-looking statements from Enveric Biosciences, Inc. include guidance on {"claim":"Enveric Biosciences' stock price will experience significant downward pressure.","entity":"ENVB","targetDate": and 1 other predictions.